Curated News
By: NewsRamp Editorial Staff
September 15, 2026
Creative Biolabs Unveils Integrated Immunology and Microfluidic Solutions
TLDR
- Creative Biolabs offers integrated anticomplementary, macrophage polarization, and microfluidic services to accelerate biotherapeutic candidate evaluation and gain a research edge.
- Creative Biolabs provides customizable assays for complement activity, M1/M2 macrophage phenotyping, and microfluidic chip development to support precise preclinical research workflows.
- Creative Biolabs advances biotherapeutics research with specialized immune assays and microfluidics, potentially leading to safer and more effective treatments for patients.
- Creative Biolabs combines immunology assays and microfluidic technologies to enable flexible, miniaturized experiments that mimic dynamic cellular conditions more accurately.
Impact - Why it Matters
As biologic modalities grow more diverse, traditional static assays and generic immunology tools often fail to capture the nuanced immune interactions that determine a candidate’s fate. Complement activation, for instance, can trigger unexpected safety signals or reduce efficacy, while macrophage polarization states can shift therapeutic outcomes in ways that simple screens miss. By offering customizable anticomplementary activity assessment, macrophage polarization analysis, and microfluidic systems that better mimic dynamic physiological conditions, Creative Biolabs is equipping researchers to generate more predictive preclinical data. This matters because better early-stage models can reduce late-stage failures, accelerate timelines, and lower costs—ultimately bringing safer, more effective biotherapeutics to patients faster. The integration of these services also reflects a broader industry shift toward holistic, context-dependent immune profiling, where no single assay tells the whole story.
Summary
Creative Biolabs, a specialized research services provider focused on complement biology and complement-targeted therapeutic development, has announced a suite of integrated capabilities designed to help researchers working with antibodies, gene therapies, nanoparticles, and other biotherapeutic candidates address complex questions in immune-response characterization, functional assessment, and experimental model selection. The Shirley, New York-based company’s offering spans anticomplementary activity assessment, macrophage polarization analysis, and customizable microfluidic solutions—all aimed at supporting early-stage candidate evaluation and preclinical research strategies.
At the core of the announcement are three specialized services. The Anticomplementary Activity Assay (ACA) helps scientists investigate complement-related effects, generating data for biotherapeutic characterization, formulation assessment, and preclinical risk evaluation. The macrophage polarization assay supports evaluation of M1/M2-associated phenotypes and polarization-related markers under various experimental conditions, proving useful for studies of immunomodulatory compounds, tumor microenvironments, inflammatory mechanisms, and therapy-induced changes in macrophage function. Additionally, the company provides one-stop microfluidic solutions that cover custom chip development and diverse research applications, enabling precise manipulation of small sample volumes, reduced reagent consumption, and dynamic cellular conditions that are difficult to reproduce with conventional static culture.
Rather than offering a one-size-fits-all approach, Creative Biolabs works with researchers to customize experimental strategies according to specific therapeutic modalities, biological questions, and study objectives. By combining immunological expertise with adaptable microfluidic technologies, the company aims to help investigators design more flexible workflows that balance sample requirements, assay throughput, and data-generation needs. Researchers can contact the scientific team to discuss project-specific requirements via the company’s complement therapeutics portal.
Source Statement
This curated news summary relied on content distributed by 24-7 Press Release. Read the original source here, Creative Biolabs Unveils Integrated Immunology and Microfluidic Solutions
